Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomize... by Vimla Naicker, Fatima Laher, Linda-Gail Bekker, Kelly E Seaton, Mary Allen, Stephen De Rosa, Nicole L Yates, Nonhlanhla N Mkhize, Kevin Saunders, Jack Heptinstall, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Chenchen Yu, Tandile Modise, Valerie Bekker, Nicole Grunenberg, Briana Furch, Maurine D Miner, Sanjay Phogat, Carlos A Diazgranados, Sanjay Gurunathan, Marguerite Koutsoukos, Olivier Van Der Meeren, Alison C Roxby, Guido Ferrari, Lynn Morris, David Montefiori, M Juliana McElrath, Georgia D Tomaras, Zoe Moodie

Get full text

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost. by Leigh H Fisher, Erica Lazarus, Chenchen Yu, Zoe Moodie, Daniel J Stieh, Nicole Yates, Lu Zhang, Sheetal Sawant, Stephen C De Rosa, Kristen W Cohen, Daryl Morris, Shannon Grant, April Randhawa, Maurine D Miner, Jenny Hendriks, Frank Wegmann, Katherine M Gill, Fatima Laher, Linda-Gail Bekker, Glenda E Gray, Lawrence Corey, M Juliana McElrath, Troy Martin, Peter B Gilbert, Georgia Tomaras, Stephen R Walsh, Lindsey R Baden, HVTN 100, HVTN 117/HPX2004 study teams

Get full text